Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Up 4.1% – Still a Buy?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shot up 4.1% during mid-day trading on Thursday . The stock traded as high as $1.28 and last traded at $1.28. 218,383 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 351,033 shares. The stock had previously closed at $1.23.

Analyst Ratings Changes

RVPH has been the subject of several research reports. Maxim Group reissued a “hold” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 16th. Benchmark reiterated a “speculative buy” rating and issued a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, August 26th. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Reviva Pharmaceuticals in a report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $14.33.

Reviva Pharmaceuticals Price Performance

The company has a market cap of $38.17 million, a PE ratio of -0.98 and a beta of -0.09. The stock has a fifty day moving average price of $1.14 and a 200-day moving average price of $1.63.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. On average, equities analysts anticipate that Reviva Pharmaceuticals Holdings, Inc. will post -0.98 earnings per share for the current year.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,001,836 shares of the company’s stock after buying an additional 26,854 shares during the quarter. Vanguard Group Inc. owned approximately 3.59% of Reviva Pharmaceuticals worth $3,787,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.